{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T04:02:31Z","timestamp":1747540951659,"version":"3.40.5"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40119-025-00400-0","type":"journal-article","created":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T23:20:55Z","timestamp":1742685655000},"page":"161-182","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Atrial FibriLlatiOn Registry (FLOW-AF): Patient Characteristics, Treatment Patterns, and Outcomes in Egypt"],"prefix":"10.1007","volume":"14","author":[{"given":"Mohamed","family":"Sobhy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdy","family":"Abdelhamid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adel Mohamed","family":"El Etriby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed Fathy Soliman","family":"Gamaleldin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed Mohamed Helmy","family":"Youssef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasha","family":"Khalife","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hany","family":"Ragy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashraf","family":"Reda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maichel","family":"Sobhy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mostafa","family":"Nawar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,21]]},"reference":[{"key":"400_CR1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41572-022-00347-9","volume":"8","author":"B Brundel","year":"2022","unstructured":"Brundel B, Ai X, True Hills M, et al. Atrial fibrillation. Nat Rev Dis Primers. 2022;8:21.","journal-title":"Nat Rev Dis Primers"},{"key":"400_CR2","first-page":"17","volume":"4","author":"K Johnston","year":"2015","unstructured":"Johnston K, Osenenko K, Qatami L, et al. Health care resource utilization and costs in individuals with atrial fibrillation in United Arab Emirates and Kingdom of Saudi Arabia: a retrospective cohort study. Int J Interna Med. 2015;4:17\u201325.","journal-title":"Int J Interna Med"},{"key":"400_CR3","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1161\/CIRCRESAHA.117.309732","volume":"120","author":"L Staerk","year":"2017","unstructured":"Staerk L, Sherer JA, Ko D, et al. Atrial fibrillation: epidemiology, pathophysiology, and clinical outcomes. Circ Res. 2017;120:1501\u201317.","journal-title":"Circ Res"},{"issue":"1","key":"400_CR4","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/00001573-200001000-00007","volume":"15","author":"S L\u00e9vy","year":"2000","unstructured":"L\u00e9vy S. Classification system of atrial fibrillation. Curr Opin Cardiol. 2000;15(1):54\u20137.","journal-title":"Curr Opin Cardiol"},{"key":"400_CR5","first-page":"331","volume":"162","author":"GD Stettin","year":"1995","unstructured":"Stettin GD. Treatment of nonvalvular atrial fibrillation. West J Med. 1995;162:331\u20139.","journal-title":"West J Med"},{"key":"400_CR6","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","volume":"285","author":"AS Go","year":"2001","unstructured":"Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA. 2001;285:2370\u20135.","journal-title":"JAMA"},{"key":"400_CR7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.9734\/ca\/2023\/v12i4344","volume":"12","author":"E Hamdy","year":"2023","unstructured":"Hamdy E, Abdallah T, Allaithy A, et al. Delta of Egypt atrial fibrillation registry phase two. Cardiol Angiol Int J. 2023;12:63\u201373.","journal-title":"Cardiol Angiol Int J"},{"key":"400_CR8","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s12916-023-02925-4","volume":"21","author":"J Sun","year":"2023","unstructured":"Sun J, Qiao Y, Zhao M, et al. Global, regional, and national burden of cardiovascular diseases in youths and young adults aged 15\u201339 years in 204 countries\/territories, 1990\u20132019: a systematic analysis of Global Burden of Disease Study 2019. BMC Med. 2023;21:222.","journal-title":"BMC Med"},{"key":"400_CR9","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41569-022-00820-8","volume":"20","author":"AD Elliott","year":"2023","unstructured":"Elliott AD, Middeldorp ME, Van Gelder IC, et al. Epidemiology and modifiable risk factors for atrial fibrillation. Nat Rev Cardiol. 2023;20:404\u201317.","journal-title":"Nat Rev Cardiol"},{"key":"400_CR10","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1080\/14779072.2018.1457953","volume":"16","author":"W Al-Shamkhani","year":"2018","unstructured":"Al-Shamkhani W, Ayetey H, Lip GYH. Atrial fibrillation in the Middle East: unmapped, underdiagnosed, undertreated. Expert Rev Cardiovasc Ther. 2018;16:341\u20138.","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"400_CR11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s43044-020-00082-0","volume":"72","author":"A Hassanin","year":"2020","unstructured":"Hassanin A, Hassanein M, Bendary A, et al. Demographics, clinical characteristics, and outcomes among hospitalized heart failure patients across different regions of Egypt. Egypt Heart J (EHJ). 2020;72:49.","journal-title":"Egypt Heart J (EHJ)"},{"key":"400_CR12","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1136\/heartjnl-2020-317656","volume":"107","author":"L Wang","year":"2021","unstructured":"Wang L, Ze F, Li J, et al. Trends of global burden of atrial fibrillation\/flutter from Global Burden of Disease Study 2017. Heart. 2021;107:881\u20137.","journal-title":"Heart"},{"key":"400_CR13","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1161\/01.CIR.0000072767.89944.6E","volume":"107","author":"T Wang","year":"2003","unstructured":"Wang T, Larson M, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation. 2003;107:2920\u20135.","journal-title":"Circulation"},{"key":"400_CR14","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.jacc.2006.10.062","volume":"49","author":"Y Miyasaka","year":"2007","unstructured":"Miyasaka Y, Barnes ME, Bailey KR, et al. Mortality trends in patients diagnosed with first atrial fibrillation: a 21-year community-based study. J Am Coll Cardiol. 2007;49:986\u201392.","journal-title":"J Am Coll Cardiol"},{"key":"400_CR15","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.joa.2017.05.004","volume":"33","author":"CE Chiang","year":"2017","unstructured":"Chiang CE, Okumura K, Zhang S, et al. 2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation. J Arrhythm. 2017;33:345\u201367.","journal-title":"J Arrhythm"},{"key":"400_CR16","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.chest.2018.07.040","volume":"154","author":"GYH Lip","year":"2018","unstructured":"Lip GYH, Banerjee A, Boriani G, et al. Antithrombotic therapy for atrial fibrillation: CHEST Guideline and Expert Panel report. Chest. 2018;154:1121\u2013201.","journal-title":"Chest"},{"key":"400_CR17","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","volume":"140","author":"CT January","year":"2019","unstructured":"January CT, Wann LS, Calkins H, et al. 2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons. Circulation. 2019;140:e125\u201351.","journal-title":"Circulation"},{"key":"400_CR18","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2021","unstructured":"Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42:373\u2013498.","journal-title":"Eur Heart J"},{"key":"400_CR19","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1007\/s12350-009-9104-y","volume":"16","author":"JV Vitola","year":"2009","unstructured":"Vitola JV, Shaw LJ, Allam AH, et al. Assessing the need for nuclear cardiology and other advanced cardiac imaging modalities in the developing world. J Nucl Cardiol. 2009;16:956\u201361.","journal-title":"J Nucl Cardiol"},{"key":"400_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.718978","volume":"9","author":"M Aboulghate","year":"2021","unstructured":"Aboulghate M, Elaghoury A, Elebrashy I, et al. The burden of obesity in Egypt. Front Public Health. 2021;9: 718978.","journal-title":"Front Public Health"},{"key":"400_CR21","volume":"14","author":"MR Abouzid","year":"2022","unstructured":"Abouzid MR, Ali K, Elkhawas I, et al. An overview of diabetes mellitus in Egypt and the significance of integrating preventive cardiology in diabetes management. Cureus. 2022;14: e27066.","journal-title":"Cureus"},{"key":"400_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.1441","volume":"6","author":"M Elbarbary","year":"2023","unstructured":"Elbarbary M, Shoeib O, El-Saied SB, et al. Prevalence and determinants of resistant hypertension in the delta region of Egypt: a prospective observational study. Health Sci Rep. 2023;6: e1441.","journal-title":"Health Sci Rep"},{"key":"400_CR23","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1016\/S0140-6736(17)30819-X","volume":"389","author":"GT Collaborators","year":"2017","unstructured":"Collaborators GT. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990\u20132015: a systematic analysis from the Global Burden of Disease Study 2015. Lancet. 2017;389:1885\u2013906.","journal-title":"Lancet"},{"key":"400_CR24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2217\/fca-2020-0014","volume":"17","author":"J-P Bassand","year":"2021","unstructured":"Bassand J-P, Apenteng P, Atar D, et al. GARFIELD-AF: a worldwide prospective registry of patients with atrial fibrillation at risk of stroke. Future Cardiol. 2021;17:19\u201338.","journal-title":"Future Cardiol"},{"key":"400_CR25","doi-asserted-by":"publisher","first-page":"704","DOI":"10.2459\/JCM.0000000000001007","volume":"21","author":"M Sobhy","year":"2020","unstructured":"Sobhy M, Khoury M, Almahmeed W, et al. The atrial FibriLlatiOn real World management registry in the Middle East and Africa: design and rationale. J Cardiovasc Med (Hagerstown). 2020;21:704\u201310.","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"400_CR26","unstructured":"R Foundation for Statistical Computing. Vienna A. R: a language and environment for statistical computing. R Core Team; 2017. https:\/\/www.R-project.org\/."},{"key":"400_CR27","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/pds.3891","volume":"25","author":"IS of Pharmacoepidemiology, Committee PP","year":"2016","unstructured":"IS of Pharmacoepidemiology, Committee PP. Guidelines for good pharmacoepidemiology practice (GPP). Pharmacoepidemiol Drug Saf. 2016;25:2\u201310.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"400_CR28","first-page":"1006","volume":"1","author":"E El-Moselhy","year":"2018","unstructured":"El-Moselhy E, Mohammed A-E, Abd El-Aziz A, et al. Coronary artery disease among elderly Egyptian patients: I. Socio-demographic, lifestyle, psychosocial, medical, and biochemical risk factors. Am J Gerentol Geriatr. 2018;1:1006.","journal-title":"Am J Gerentol Geriatr"},{"key":"400_CR29","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1161\/CIRCOUTCOMES.110.959700","volume":"4","author":"M Zubaid","year":"2011","unstructured":"Zubaid M, Rashed WA, Alsheikh-Ali AA, et al. Gulf Survey of Atrial Fibrillation Events (Gulf SAFE): design and baseline characteristics of patients with atrial fibrillation in the Arab Middle East. Circ Cardiovasc Qual Outcomes. 2011;4:477\u201382.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"400_CR30","doi-asserted-by":"publisher","first-page":"93","DOI":"10.4103\/ajm.ajm_228_20","volume":"11","author":"M El Kadri","year":"2021","unstructured":"El Kadri M, Ghorab A, Joury J, et al. Patient characteristics, adherence, and costs of oral anticoagulation therapy in non-valvular atrial fibrillation using the Dubai Real-World Claims Database. Avicenna J Med. 2021;11:93\u2013102.","journal-title":"Avicenna J Med"},{"key":"400_CR31","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1007\/s12325-021-01670-5","volume":"38","author":"BY Sayin","year":"2021","unstructured":"Sayin BY, Al Mahmeed W, Ragy HI, et al. Middle East treatment strategies and clinical outcomes in patients with atrial fibrillation: one-year follow-up data from Garfield-AF study. Adv Ther. 2021;38:2391\u2013405.","journal-title":"Adv Ther"},{"key":"400_CR32","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.jacep.2015.02.019","volume":"1","author":"S Fumagalli","year":"2015","unstructured":"Fumagalli S, Said SAM, Laroche C, et al. Age-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: the EORP-AF general pilot registry (EURObservational research programme-atrial fibrillation). JACC Clin Electrophysiol. 2015;1:326\u201334.","journal-title":"JACC Clin Electrophysiol"},{"key":"400_CR33","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.cjca.2020.04.026","volume":"37","author":"R Sandhu","year":"2021","unstructured":"Sandhu R, Wilton S, Islam S, et al. Temporal trends in population rates of incident atrial fibrillation and atrial flutter hospitalizations, stroke risk, and mortality show decline in hospitalizations. Can J Cardiol. 2021;37:310\u20138.","journal-title":"Can J Cardiol"},{"key":"400_CR34","doi-asserted-by":"publisher","first-page":"e0265498","DOI":"10.1371\/journal.pone.0265498","volume":"17","author":"A Alonso","year":"2022","unstructured":"Alonso A, Alam A, Kamel H, et al. Epidemiology of atrial fibrillation in the All of Us Research Program. PLoS ONE. 2022;17:e0265498.","journal-title":"PLoS ONE"},{"issue":"2","key":"400_CR35","doi-asserted-by":"publisher","first-page":"e001794","DOI":"10.1136\/openhrt-2021-001794","volume":"8","author":"SC Harb","year":"2021","unstructured":"Harb SC, Wang TKM, Nemer D, Wu Y, Cho L, Menon V, et al. CHA2DS2-VASc score stratifies mortality risk in patients with and without atrial fibrillation. Open Heart. 2021;8(2):e001794.","journal-title":"Open Heart."},{"issue":"1","key":"400_CR36","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/s12872-023-03375-9","volume":"23","author":"S Kularatna","year":"2023","unstructured":"Kularatna S, Jadambaa A, Hewage S, Brain D, McPhail S, Parsonage W. Global, regional, and national burden of heart failure associated with atrial fibrillation. BMC Cardiovasc Disord. 2023;23(1):345.","journal-title":"BMC Cardiovasc Disord"},{"key":"400_CR37","first-page":"64","volume":"12","author":"A Alharbi","year":"2018","unstructured":"Alharbi A, Alsuhaibani M. Atrial fibrillation among adult Saudi patients with chronic heart failure: Tertiary Center experience. Int J Health Sci. 2018;12:64\u20138.","journal-title":"Int J Health Sci"},{"key":"400_CR38","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1177\/1753944712464101","volume":"7","author":"J LaMori","year":"2013","unstructured":"LaMori J, Mody S, Gross H, et al. Burden of comorbidities among patients with atrial fibrillation. Ther Adv Cardiovasc Dis. 2013;7:53\u201362.","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"400_CR39","doi-asserted-by":"publisher","first-page":"e16560","DOI":"10.1097\/MD.0000000000016560","volume":"98","author":"A Ga\u017eov\u00e1","year":"2019","unstructured":"Ga\u017eov\u00e1 A, Leddy J, Rexov\u00e1 M, et al. Predictive value of CHA2DS2-VASc scores regarding the risk of stroke and all-cause mortality in patients with atrial fibrillation (CONSORT compliant). Medicine. 2019;98:e16560.","journal-title":"Medicine"},{"key":"400_CR40","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1093\/europace\/euu155","volume":"17","author":"GY Lip","year":"2015","unstructured":"Lip GY, Laroche C, Boriani G, et al. Sex-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Observational Research Programme Pilot survey on Atrial Fibrillation. Europace. 2015;17:24\u201331.","journal-title":"Europace"},{"key":"400_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2020.104703","volume":"29","author":"THM Elkhatib","year":"2020","unstructured":"Elkhatib THM, Elsaid AF, Al-Molla RM, et al. Prevalence and associated risk factors of cerebral microbleeds in Egyptian patients with acute ischemic stroke and atrial fibrillation. J Stroke Cerebrovasc Dis. 2020;29: 104703.","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"400_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0249524","volume":"16","author":"M Koziel","year":"2021","unstructured":"Koziel M, Teutsch C, Halperin JL, et al. Atrial fibrillation and comorbidities: clinical characteristics and antithrombotic treatment in GLORIA-AF. PLoS ONE. 2021;16: e0249524.","journal-title":"PLoS ONE"},{"key":"400_CR43","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2147\/VHRM.S360822","volume":"18","author":"Z Alhaddad","year":"2022","unstructured":"Alhaddad Z, Hammoudeh A, Khader Y, et al. Demographics and risk profile of elderly Middle Eastern patients with atrial fibrillation: the Jordan Atrial Fibrillation (JoFib) study. Vasc Health Risk Manag. 2022;18:289\u201395.","journal-title":"Vasc Health Risk Manag"},{"key":"400_CR44","first-page":"5515089","volume":"2021","author":"AJ Hammoudeh","year":"2021","unstructured":"Hammoudeh AJ, Khader Y, Kadri N, et al. Adherence to the 2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline on the use of oral anticoagulant agents in Middle Eastern patients with atrial fibrillation: the Jordan Atrial Fibrillation (JoFib) study. Int J Vasc Med. 2021;2021:5515089.","journal-title":"Int J Vasc Med"},{"key":"400_CR45","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1160\/TH17-08-0555","volume":"117","author":"M Mazurek","year":"2017","unstructured":"Mazurek M, Huisman MV, Rothman KJ, et al. Regional differences in antithrombotic treatment for atrial fibrillation: insights from the GLORIA-AF phase II registry. Thromb Haemost. 2017;117:2376\u201388.","journal-title":"Thromb Haemost"},{"key":"400_CR46","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1093\/europace\/eux301","volume":"20","author":"G Boriani","year":"2018","unstructured":"Boriani G, Proietti M, Laroche C, et al. Contemporary stroke prevention strategies in 11 096 European patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) Long-Term General Registry. Europace. 2018;20:747\u201357.","journal-title":"Europace"},{"key":"400_CR47","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","volume":"383","author":"CT Ruff","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955\u201362.","journal-title":"Lancet"},{"key":"400_CR48","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j5058","volume":"359","author":"JA Lopez-Lopez","year":"2017","unstructured":"Lopez-Lopez JA, Sterne JAC, Thom HHZ, et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost-effectiveness analysis. BMJ. 2017;359: j5058.","journal-title":"BMJ"},{"key":"400_CR49","unstructured":"Apixaban Dosage Drugs.com2023. https:\/\/www.drugs.com\/dosage\/apixaban.html."},{"key":"400_CR50","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1177\/0003319714536980","volume":"66","author":"M Zubaid","year":"2015","unstructured":"Zubaid M, Rashed WA, Alsheikh-Ali AA, et al. Management and 1-year outcomes of patients with atrial fibrillation in the Middle East: Gulf survey of atrial fibrillation events. Angiology. 2015;66:464\u201371.","journal-title":"Angiology"},{"key":"400_CR51","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s11239-017-1519-8","volume":"44","author":"S Helmert","year":"2017","unstructured":"Helmert S, Marten S, Mizera H, et al. Effectiveness and safety of apixaban therapy in daily-care patients with atrial fibrillation: results from the Dresden NOAC Registry. J Thromb Thrombolysis. 2017;44:169\u201378.","journal-title":"J Thromb Thrombolysis"},{"key":"400_CR52","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2017-000682","volume":"4","author":"L Friberg","year":"2017","unstructured":"Friberg L, Oldgren J. Efficacy and safety of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation. Open Heart. 2017;4: e000682.","journal-title":"Open Heart"},{"key":"400_CR53","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/clc.23558","volume":"44","author":"S Ouali","year":"2021","unstructured":"Ouali S, Ben Halima A, Chabrak S, et al. Epidemiological characteristics, management, and outcomes of atrial fibrillation in TUNISIA: results from the National Tunisian Registry of Atrial Fibrillation (NATURE-AF). Clin Cardiol. 2021;44:501\u201310.","journal-title":"Clin Cardiol"},{"key":"400_CR54","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1016\/j.ijcard.2013.02.003","volume":"168","author":"S Apostolakis","year":"2013","unstructured":"Apostolakis S, Zubaid M, Rashed WA, et al. Assessment of stroke risk in Middle Eastern patients with atrial fibrillation: the Gulf SAFE registry. Int J Cardiol. 2013;168:1644\u20136.","journal-title":"Int J Cardiol"},{"key":"400_CR55","volume-title":"Health care systems and policies","author":"C Gericke","year":"2018","unstructured":"Gericke C, Britain K, Elmahdawy M, et al. Health system in Egypt. In: Ginneken E, Busse R, editors., et al., Health care systems and policies. New York: Springer; 2018."}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-025-00400-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-025-00400-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-025-00400-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T04:03:21Z","timestamp":1747454601000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40119-025-00400-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,21]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["400"],"URL":"https:\/\/doi.org\/10.1007\/s40119-025-00400-0","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"type":"print","value":"2193-8261"},{"type":"electronic","value":"2193-6544"}],"subject":[],"published":{"date-parts":[[2025,3,21]]},"assertion":[{"value":"19 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Magdy Abdelhamid received speaker honoraria from Pfizer, Novartis, and AstraZeneca, is an advisory board member with Bayer, and received research grants or other funding from Pfizer. Mohamed Sobhy, Adel Mohamed El Etriby, Hany Ragy, Ashraf Reda, Maichel Sobhy, and Mostafa Nawar have no conflicts to disclose. Natasha Khalife is an employee of IQVIA, which conducted the study on behalf of the sponsor. Mohamed Fathy Soliman Gamaleldin and Ahmed Mohamed Helmy Youssef are employees of Pfizer Inc., the study sponsor.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study protocol (available upon request) was submitted and approved by the Alexandria University Hospital (MOH) Ethics Committee and the Institutional Review Board of each participating hospital (Table S4, Supplementary Material). The registry was conducted in accordance with the principles of the Declaration of Helsinki, local regulatory requirements, and the International Conference on Harmonisation Good Pharmacoepidemiological and Clinical Practice guidelines []. All study participants provided written informed consent, and the confidentiality and anonymity of all enrolled patients were maintained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}